The US Food and Drug Administration (FDA) has approved the novel calcimimetic etelcalcetide (Parsabiv, Amgen) for the treatment of secondary hyperparathyroidism in adults on hemodialysis.

A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012. REUTERS/Jason Reed/File Photo (Reuters) - The U.S. Food and Drug Administration has ...

Please provide your email address to receive an email when new articles are posted on . Adults who underwent Roux-en-Y gastric bypass who were also vitamin D deficient had an increased risk for ...

Please provide your email address to receive an email when new articles are posted on . A lower parathyroid hormone target treatment method was linked with reduced adjusted hazard of death. The ...

DUBLIN--(BUSINESS WIRE)--The "Secondary Hyperparathyroidism Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ...

Doxercalciferol and calcitriol are equally effective at modulating serum parathyroid hormone levels, bone turnover and fibroblast growth factor 23 (FGF-23) in pediatric patients with secondary ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/nk2xkm/secondary) has announced the addition of the "Secondary ...

In a retrospective study, investigators found that radiofrequency ablation and parathyroidectomy for secondary hyperparathyroidism in patients on dialysis achieved intact parathyroid hormone levels in ...

This study evaluated the health-economic consequences of use of intravenous paricalcitol (Zemplar ®), oral calcitriol or oral and intravenous alfacalcidol for the treatment of patients with secondary ...

dialysis hemodialysis machine The hospitalization rate and number of hospital days increased significantly in the year after parathyroidectomy vs the year before, whereas dialysis visits and office ...